These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis. Tao K; Tzou PL; Kosakovsky Pond SL; Ioannidis JPA; Shafer RW Microbiol Spectr; 2022 Aug; 10(4):e0092622. PubMed ID: 35700134 [TBL] [Abstract][Full Text] [Related]
6. COVID-19 treatments approved in the European Union and clinical recommendations for the management of non-hospitalized and hospitalized patients. Bellino S Ann Med; 2022 Dec; 54(1):2856-2860. PubMed ID: 36259490 [TBL] [Abstract][Full Text] [Related]
7. ESCMID COVID-19 guidelines: diagnostic testing for SARS-CoV-2. Fragkou PC; De Angelis G; Menchinelli G; Can F; Garcia F; Morfin-Sherpa F; Dimopoulou D; Mack E; de Salazar A; Grossi A; Lytras T; Skevaki C Clin Microbiol Infect; 2022 Jun; 28(6):812-822. PubMed ID: 35218978 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. Montgomery H; Hobbs FDR; Padilla F; Arbetter D; Templeton A; Seegobin S; Kim K; Campos JAS; Arends RH; Brodek BH; Brooks D; Garbes P; Jimenez J; Koh GCKW; Padilla KW; Streicher K; Viani RM; Alagappan V; Pangalos MN; Esser MT; Lancet Respir Med; 2022 Oct; 10(10):985-996. PubMed ID: 35688164 [TBL] [Abstract][Full Text] [Related]
9. Cilgavimab/Tixagevimab as alternative therapeutic approach for BA.2 infections. Dichtl S; Zaderer V; Kozubowski V; Abd El Halim H; Lafon E; Lanser L; Weiss G; Lass-Flörl C; Wilflingseder D; Posch W Front Med (Lausanne); 2022; 9():1005589. PubMed ID: 36250084 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2. Fiaschi L; Dragoni F; Schiaroli E; Bergna A; Rossetti B; Giammarino F; Biba C; Gidari A; Lai A; Nencioni C; Francisci D; Zazzi M; Vicenti I Viruses; 2022 Jun; 14(7):. PubMed ID: 35891355 [TBL] [Abstract][Full Text] [Related]
11. Japanese rapid/living recommendations on drug management for COVID-19: updated guidelines (July 2022). Yamakawa K; Yamamoto R; Terayama T; Hashimoto H; Ishihara T; Ishimaru G; Imura H; Okano H; Narita C; Mayumi T; Yasuda H; Yamada K; Yamada H; Kawasaki T; Shime N; Doi K; Egi M; Ogura H; Aihara M; Kushimoto S; Nishida O; Acute Med Surg; 2022; 9(1):e789. PubMed ID: 36267628 [TBL] [Abstract][Full Text] [Related]
12. Asia Pacific perspectives on the second year of the COVID-19 pandemic: A follow-up survey. Pawankar R; Thong BY; Tiongco-Recto M; Wang JY; Latiff AHA; Leung TF; Li PH; Lobo RCM; Lucas M; Oh JW; Kamchaisatian W; Nagao M; Rengganis I; Udwadia ZF; Dhar R; Munkhbayarlakh S; Narantsetseg L; Pham DL; Zhang Y; Zhang L Clin Exp Allergy; 2022 Aug; 52(8):965-973. PubMed ID: 35906963 [TBL] [Abstract][Full Text] [Related]
14. A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment. Focosi D; Casadevall A Viruses; 2022 Sep; 14(9):. PubMed ID: 36146805 [TBL] [Abstract][Full Text] [Related]
15. In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5. Touret F; Baronti C; Pastorino B; Villarroel PMS; Ninove L; Nougairède A; de Lamballerie X Sci Rep; 2022 Jul; 12(1):12609. PubMed ID: 35871089 [TBL] [Abstract][Full Text] [Related]
16. Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern. Mazzaferri F; Mirandola M; Savoldi A; De Nardo P; Morra M; Tebon M; Armellini M; De Luca G; Calandrino L; Sasset L; D'Elia D; Sozio E; Danese E; Gibellini D; Monne I; Scroccaro G; Magrini N; Cattelan A; Tascini C; ; Tacconelli E Elife; 2022 Nov; 11():. PubMed ID: 36413383 [TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants. Brehm TT; Pfefferle S; von Possel R; Karolyi M; Zoufaly A; Wichmann D; Kobbe R; Emmerich P; Nörz D; Aepfelbacher M; Schulze Zur Wiesch J; Addo MM; Schmiedel S; Lütgehetmann M J Med Virol; 2022 Oct; 94(10):5038-5043. PubMed ID: 35662058 [TBL] [Abstract][Full Text] [Related]
18. Care for adults with COVID-19: living guidelines from the National COVID-19 Clinical Evidence Taskforce. White H; McDonald SJ; Barber B; Davis J; Burr L; Nair P; Mukherjee S; Tendal B; Elliott J; McGloughlin S; Turner T Med J Aust; 2022 Oct; 217(7):368-378. PubMed ID: 36150213 [TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Stella AO; Kindinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Jean T; Foster CSP; Christ D; Hoppe AC; Munier ML; Darley D; Churchill M; Stark DJ; Matthews G; Rawlinson WD; Kelleher AD; Turville SG EBioMedicine; 2022 Oct; 84():104270. PubMed ID: 36130476 [TBL] [Abstract][Full Text] [Related]
20. Antiviral Treatment of Coronavirus Disease-2019 Pneumonia. Radcliffe C; Malinis M; Azar MM Clin Chest Med; 2023 Jun; 44(2):279-297. PubMed ID: 37085220 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]